Liraglutide for perioperative management of hyperglycaemia in cardiac surgery patients: a multicentre randomized superiority trial.

Hulst AH, Visscher MJ, Godfried MB, Thiel B, Gerritse BM, Scohy TV, Bouwman RA, Willemsen MGA, Hollmann MW, Preckel B, DeVries JH, Hermanides J

Diabetes, obesity & metabolism17 Dec 2019Cited by 59 (Europe PMC)

PMID31749275PMCIDPMC7079116DOI10.1111/dom.13927PepBankPUB-31749275

Read at source PubMedAsk about this study

Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults having cardiac surgery, fewer patients needed additional insulin with preoperative liraglutide than with placebo.
In plain wordsIn adults having heart surgery, fewer patients needed extra insulin after liraglutide than after placebo.
Peptide
Liraglutide
Outcome
DecreasePatients needing insulin for blood glucose >8.0 mmol/L in theatre
Study
n = 261
Comparator
Placebo
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.6 mg the evening before surgery and 1.2 mg after induction of anaesthesia · subcutaneousAs given in this study (human).
Measurements
Patients needing additional insulin
43%
liraglutide
Patients needing additional insulin
61%
placebo
Source sentences
Summary
In the liraglutide group, 55 (43%) patients required additional insulin compared with 80 (61%) in the placebo group and absolute difference 18% (95% confidence interval 5.9-30.0, P = 0.003).
2 context sentences(design, population, supporting numbers)
Summary · context
The primary outcome was insulin administration for blood glucose >8.0 mmol/L in the operating theatre.
Summary · context
In this randomized, blinded, placebo-controlled, parallel-group, balanced (1:1), multicentre randomized, superiority trial, adult patients undergoing cardiac surgery in four Dutch tertiary hospitals were randomized to receive 0.6 mg subcutaneous liraglutide on the evening before surgery and 1.2 mg a…
Report a problemFND-3174927501
02HumanRandomized controlled trialEfficacy outcome
In adults having cardiac surgery, the insulin dose was significantly lower with preoperative liraglutide than with placebo.
In plain wordsIn adults having heart surgery, liraglutide lowered the insulin dose needed compared with placebo.
Peptide
Liraglutide
Outcome
DecreaseInsulin dose
Study
n = 261
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.6 mg the evening before surgery and 1.2 mg after induction of anaesthesia · subcutaneousAs given in this study (human).
Source sentences
Summary
Dose and number of insulin injections and mean blood glucose were all significantly lower in the liraglutide group.
1 context sentence(design, population, supporting numbers)
Summary · context
In this randomized, blinded, placebo-controlled, parallel-group, balanced (1:1), multicentre randomized, superiority trial, adult patients undergoing cardiac surgery in four Dutch tertiary hospitals were randomized to receive 0.6 mg subcutaneous liraglutide on the evening before surgery and 1.2 mg a…
Report a problemFND-3174927502
03HumanRandomized controlled trialEfficacy outcome
In adults having cardiac surgery, the number of insulin injections was significantly lower with preoperative liraglutide than with placebo.
In plain wordsIn adults having heart surgery, liraglutide reduced the number of insulin injections needed compared with placebo.
Peptide
Liraglutide
Outcome
DecreaseNumber of insulin injections
Study
n = 261
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.6 mg the evening before surgery and 1.2 mg after induction of anaesthesia · subcutaneousAs given in this study (human).
Source sentences
Summary
Dose and number of insulin injections and mean blood glucose were all significantly lower in the liraglutide group.
1 context sentence(design, population, supporting numbers)
Summary · context
In this randomized, blinded, placebo-controlled, parallel-group, balanced (1:1), multicentre randomized, superiority trial, adult patients undergoing cardiac surgery in four Dutch tertiary hospitals were randomized to receive 0.6 mg subcutaneous liraglutide on the evening before surgery and 1.2 mg a…
Report a problemFND-3174927503
04HumanRandomized controlled trialEfficacy outcome
In adults having cardiac surgery, mean blood glucose was significantly lower with preoperative liraglutide than with placebo.
In plain wordsIn adults having heart surgery, liraglutide led to lower average blood sugar than placebo.
Peptide
Liraglutide
Outcome
DecreaseMean blood glucose
Study
n = 261
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
0.6 mg the evening before surgery and 1.2 mg after induction of anaesthesia · subcutaneousAs given in this study (human).
Source sentences
Summary
Dose and number of insulin injections and mean blood glucose were all significantly lower in the liraglutide group.
1 context sentence(design, population, supporting numbers)
Summary · context
In this randomized, blinded, placebo-controlled, parallel-group, balanced (1:1), multicentre randomized, superiority trial, adult patients undergoing cardiac surgery in four Dutch tertiary hospitals were randomized to receive 0.6 mg subcutaneous liraglutide on the evening before surgery and 1.2 mg a…
Report a problemFND-3174927504
05HumanRandomized controlled trialSafety outcome
In adults having cardiac surgery, the incidence of hypoglycaemia did not differ between liraglutide and placebo.
In plain wordsIn adults having heart surgery, liraglutide did not change how often low blood sugar happened compared with placebo.
Peptide
Liraglutide
Outcome
No significant changeIncidence of hypoglycaemia
Study
n = 261
Comparator
Placebo
Outcome group
Adverse events · Metabolic and weight
Studied dose
0.6 mg the evening before surgery and 1.2 mg after induction of anaesthesia · subcutaneousAs given in this study (human).
Source sentences
Summary
We observed no difference in the incidence of hypoglycaemia, nausea and vomiting, mortality or postoperative complications.
1 context sentence(design, population, supporting numbers)
Summary · context
In this randomized, blinded, placebo-controlled, parallel-group, balanced (1:1), multicentre randomized, superiority trial, adult patients undergoing cardiac surgery in four Dutch tertiary hospitals were randomized to receive 0.6 mg subcutaneous liraglutide on the evening before surgery and 1.2 mg a…
Report a problemFND-3174927505
06HumanRandomized controlled trialSafety outcome
In adults having cardiac surgery, the incidence of nausea and vomiting did not differ between liraglutide and placebo.
In plain wordsIn adults having heart surgery, liraglutide did not change how often nausea and vomiting happened compared with placebo.
Peptide
Liraglutide
Outcome
No significant changeIncidence of nausea and vomiting
Study
n = 261
Comparator
Placebo
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
0.6 mg the evening before surgery and 1.2 mg after induction of anaesthesia · subcutaneousAs given in this study (human).
Source sentences
Summary
We observed no difference in the incidence of hypoglycaemia, nausea and vomiting, mortality or postoperative complications.
1 context sentence(design, population, supporting numbers)
Summary · context
In this randomized, blinded, placebo-controlled, parallel-group, balanced (1:1), multicentre randomized, superiority trial, adult patients undergoing cardiac surgery in four Dutch tertiary hospitals were randomized to receive 0.6 mg subcutaneous liraglutide on the evening before surgery and 1.2 mg a…
Report a problemFND-3174927506
07HumanRandomized controlled trialSafety outcome
In adults having cardiac surgery, mortality did not differ between liraglutide and placebo.
In plain wordsIn adults having heart surgery, liraglutide did not change the number of deaths compared with placebo.
Peptide
Liraglutide
Outcome
No significant changeMortality
Study
n = 261
Comparator
Placebo
Outcome group
Mortality · Whole body
Studied dose
0.6 mg the evening before surgery and 1.2 mg after induction of anaesthesia · subcutaneousAs given in this study (human).
Source sentences
Summary
We observed no difference in the incidence of hypoglycaemia, nausea and vomiting, mortality or postoperative complications.
1 context sentence(design, population, supporting numbers)
Summary · context
In this randomized, blinded, placebo-controlled, parallel-group, balanced (1:1), multicentre randomized, superiority trial, adult patients undergoing cardiac surgery in four Dutch tertiary hospitals were randomized to receive 0.6 mg subcutaneous liraglutide on the evening before surgery and 1.2 mg a…
Report a problemFND-3174927507
08HumanRandomized controlled trialSafety outcome
In adults having cardiac surgery, postoperative complications did not differ between liraglutide and placebo.
In plain wordsIn adults having heart surgery, liraglutide did not change how often complications after surgery happened compared with placebo.
Peptide
Liraglutide
Outcome
No significant changePostoperative complications
Study
n = 261
Comparator
Placebo
Outcome group
Adverse events · Whole body
Studied dose
0.6 mg the evening before surgery and 1.2 mg after induction of anaesthesia · subcutaneousAs given in this study (human).
Source sentences
Summary
We observed no difference in the incidence of hypoglycaemia, nausea and vomiting, mortality or postoperative complications.
1 context sentence(design, population, supporting numbers)
Summary · context
In this randomized, blinded, placebo-controlled, parallel-group, balanced (1:1), multicentre randomized, superiority trial, adult patients undergoing cardiac surgery in four Dutch tertiary hospitals were randomized to receive 0.6 mg subcutaneous liraglutide on the evening before surgery and 1.2 mg a…
Report a problemFND-3174927508

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.